*The following content is generated by AI and is for reference only.
<h3>Overview</h3>
<p>A fixed-dose combination antiretroviral therapy containing <strong>Dolutegravir</strong>, <strong>Lamivudine</strong>, and <strong>Tenofovir Disoproxil Fumarate</strong>. This pharmaceutical grade API blend utilizes advanced crystallization for high purity. CAS: 140826-57-5 (DTG), 134678-17-4 (TDF), 134678-17-4 (Lamivudine).</p>
<h3>Application</h3>
<ul>
<li>HIV-1 treatment in adults and adolescents.</li>
<li>Virologic suppression maintenance therapy.</li>
<li>First-line regimen in resource-limited settings.</li>
</ul>
<h3>Precautions</h3>
<p>Contraindicated with strong inducers of UGT1A1/ABC transporters. Store below 30°C in dry conditions to prevent hydrolysis. Monitor renal function and bone density during long-term use.</p>